Payment overview · 2025
General Payments
$136.89
4 reported records · 4 companies
Healthcare provider profile · identity verified
Juanita Yoder Albright, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FISHERS, IN · NPI 1528041852
Verified facts
What the public records show
CMS Open Payments records show Juanita Yoder Albright, MD received $136.89 in general payments during 2025 across 4 reported records.
Novo Nordisk Inc accounted for 78.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $107.76 | 78.7% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $14.55 | 10.6% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $7.76 | 5.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.82 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $136.89 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $107.76 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $7.76 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 132 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 718 | 193 |
| Levothyroxine Sodium | Levothyroxine Sodium | 665 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 639 | 152 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 533 | 159 |
| Losartan Potassium | Losartan Potassium | 424 | 108 |
| Sertraline Hcl | Sertraline Hcl | 385 | 103 |
| Omeprazole | Omeprazole | 359 | 100 |
| Lisinopril | Lisinopril | 340 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 317 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 61 |
| Gabapentin | Gabapentin | 240 | 67 |
| Famotidine | Famotidine | 228 | 77 |
| Trazodone Hcl | Trazodone Hcl | 216 | 64 |
| Metformin Hcl | Metformin Hcl | 211 | 46 |
| Meloxicam | Meloxicam | 208 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 56 |
| Simvastatin | Simvastatin | 167 | 44 |
| Celecoxib | Celecoxib | 162 | 52 |
| Eliquis | Apixaban | 154 | 35 |
| Furosemide | Furosemide | 142 | 29 |
| Allopurinol | Allopurinol | 138 | 29 |
| Buspirone Hcl | Buspirone Hcl | 138 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 133 | 38 |
| Synthroid | Levothyroxine Sodium | 133 | 36 |
| Bupropion Xl | Bupropion Hcl | 132 | 32 |
| Ozempic | Semaglutide | 132 | 26 |
| Valsartan | Valsartan | 131 | 30 |
| Tramadol Hcl | Tramadol Hcl | 129 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 54 |
| Carvedilol | Carvedilol | 124 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 114 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 31 |
| Metformin Hcl Er | Metformin Hcl | 111 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 28 |
| Lovastatin | Lovastatin | 105 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 27 |
| Alendronate Sodium | Alendronate Sodium | 103 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 103 | 23 |
| Myrbetriq | Mirabegron | 102 | 24 |
| Potassium Chloride | Potassium Chloride | 98 | 20 |
| Mounjaro | Tirzepatide | 92 | 12 |
| Estradiol | Estradiol | 82 | 27 |
| Glipizide Er | Glipizide | 81 | 23 |
| Montelukast Sodium | Montelukast Sodium | 81 | 23 |
| Memantine Hcl | Memantine Hcl | 80 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 20 |
| Prednisone | Prednisone | 74 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 69 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 17 |
| Ezetimibe | Ezetimibe | 62 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 57 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 56 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 17 |
| Trulicity | Dulaglutide | 56 | suppressed |
| Methylprednisolone | Methylprednisolone | 55 | 48 |
| Warfarin Sodium | Warfarin Sodium | 55 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 18 |
| Torsemide | Torsemide | 52 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | 15 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Alprazolam | Alprazolam | 51 | 19 |
| Januvia | Sitagliptin Phosphate | 47 | 18 |
| Mirtazapine | Mirtazapine | 46 | 12 |
| Spironolactone | Spironolactone | 46 | 14 |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Cephalexin | Cephalexin | 44 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Glimepiride | Glimepiride | 41 | suppressed |
| Irbesartan | Irbesartan | 41 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 11 |
| Atenolol | Atenolol | 37 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 37 | 11 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Azithromycin | Azithromycin | 34 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | 13 |
| Acyclovir | Acyclovir | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 27 | 22 |
| Prolia | Denosumab | 27 | 16 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 11 |
| Finasteride | Finasteride | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 13 |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 19 |
| Arnuity Ellipta | Fluticasone Furoate | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 15 |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 19 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Xifaxan | Rifaximin | 18 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 13 |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | 11 |
| Risperidone | Risperidone | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $136.89 · 4 records | Novo Nordisk Inc | Azstarys, Doc Band, Ozempic, VOQUEZNA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error